Developing a Personalized Decision Support Tool for Using the Levonorgestrel-Releasing Intrauterine System to Prevent Endometrial Cancer

What this Trial Is About

Researchers are developing a personalized educational tool to help women and healthcare professionals make informed decisions about using the levonorgestrel-releasing intrauterine system LNG-IUS to prevent endometrial cancer. The study focuses on women at risk of the disease and aims to support shared decision-making without replacing consultations with clinicians. This tool intends to incorporate patient values, experiences, and a personalized risk calculator for endometrial cancer. The study is divided into two phases. The first phase involves identifying the decisional needs, preferences, and values of participants regarding LNG-IUS through surveys and interviews. The second phase focuses on creating and testing a web-based shared decision-making tool available in English and Spanish, which includes a personalized risk calculator and targets LNG-IUS as a prevention strategy. Participants will complete questionnaires and interviews to assess their preferences and experiences. The study will track outcomes using patient utility questionnaires over about one year to evaluate the tools effectiveness. Participants include unaffected women, women with a history of endometrial cancer or complex atypical hyperplasia, and healthcare providers. The study spans from early 2026 to early 2030, with ongoing data collection and analysis throughout.

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer